Gerard Vaillant is a former Johnson & Johnson worldwide diagnostics group chairman (1994-2004).

Prior to that, he held numerous executive positions such as worldwide President of Lifescan (1992-1995), was member of the J&J medical devices group operating committee and VP J&J International (1987-1992). He also chaired Patho Quest S.A.S.

Gerard holds an education degree in Marketing from Ecole Superieure de Commerce, Paris and a Master in Sciences from University of Sciences, Paris.

He is currently acting as Chairman for STAT-Dx.

Raúl Martín-Ruiz is a Principal in Ysios Capital, a leading independent Spanish venture capital firm that provides private equity financing to human healthcare and life sciences companies. Prior to joining Ysios in 2008 he developed his career in Laboratorios Almirall, initially working in corporate business development (Licensing In and Licensing Out) and then as responsible for developing and managing the business of the company in the Americas and Africa through licensees and distributors.

Initially he was trained as a researcher in the areas of Central Nervous System pharmacology in the Department of Pharmacology of the UPV-EHU (University of the Basque Country), and in neurochemistry in the Department of Neurochemistry of the IIBB-CSIC (Institute for Biomedical Research of Barcelona-Spanish National Research Council).

He is a Member of the Board of Directors of STAT-Dx and Prexton Therapeutics. He has a B.Sc. in Biological Sciences by the UPV-EHU and holds a Ph.D. in Neurosciences by the same university and the CSIC.

Master in Molecular Biology (Paris VI) and Master in Finance and Innovation Management (Masternova - AgroPariTech). Started at CDC Innovation from 2000 to 2003, later joining AGF Private Equity (now Idinvest Partners) where he developed the investment activity in the life sciences and made investments such as Novagali Pharma (listed on Euronext and acquired by Santen) Prosensa Therapeutics (listed on Nasdaq and acquired by Biomarin) Vivacta (acquired by Novartis), IntegraGen (listed on Alternext) Onxeo (listed on Euronext).

Rémi joined Kurma Partners in 2010 and is in charge of investments in AM Pharma (The Netherlands), Orphazyme (Denmark), Oxthera (Sweden), STAT-Dx (Spain), Pharvaris (The Netherlands), Dynacure (France) and Zealand Pharma (Denmark).

Arthur Franken joined Gilde in 2001. He is focusing on venture and growth capital investments in the biopharm, medtech, diagnostics and digital health sectors. He led the investments in Breath Therapeutics, Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche), ProQR Therapeutics (IPO on NASDAQ) and STAT-Dx. He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext), Agendia, uniQure (IPO on NASDAQ), BG Medicine (IPO on NASDAQ) and Pieris (IPO on NASDAQ).

He represents Gilde on the boards of Breath Therapeutics, Levicept, Moximed, STAT-Dx and Symphogen. He served as a board member for FlowCardia, MTM Laboratories and ProQR Therapeutics until the trade sales or IPO.

Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.

Frank Kalkbrenner is Managing Director of the Boehringer Ingelheim Corporate Venture Fund (BIVF). Over the last seven years, he has been involved in numerous investments and exits of the fund. Currently, he serves as Board member of Hookipa Biotech in Vienna, STAT-Dx in Barcelona, Eyevensys in Paris, Acousia Therapeutics in Tübingen and Inserm Transfer Initiative, a French Seed Investment Fund; in addition, he is Board observer of Amal Therapeutics in Geneva.

Frank studied medicine and holds a degree in Pharmacology and Toxicology. He spent more than 10 years in academic research in the Max-Planck-Institute for Molecular Genetics in Berlin and in the Institute of Pharmacology of the Freie Universität, Berlin. His academic research focused on gene regulation and membrane signal transduction.

In 1997, he started his industrial career by joining Schering AG as senior scientist in Experimental Dermatology. In 1999, Frank joined Boehringer Ingelheim (BI) and subsequently held several positions in Pulmonary Research. In 2005, he took over the responsibility for the Licensing Department of BI Germany. In 2010, he joined the Boehringer Ingelheim Venture Fund.

Jose Antonio is the Investment Director at Caixa Capital Risc. He specializes in investment in biotechnology and medical devices. He currently serves on the Board of Directors at Laboratoris Sanfit, Aelix Therapeutics, mTrap and Genmedica Therapeutics. He is responsible for the analysis, negotiation and structuring of processes in life science companies. Jose A. has more than 10 years of experience in the analysis of investment opportunities and specializes in the creation of companies in the healthcare sector.

His experience began in the Department of Business Development at Genzyme Corporation, a company specializing in the development and commercialization of drugs for orphan diseases. He later joined the Technology Portfolio team at Genoma España, a public sector foundation that promotes technology development, knowledge transfer and innovation, particularly in the biotechnology sector, where he specialized in the analysis of investment opportunities in start-up companies. Jose Antonio holds a degree in Biology and a Masters in Corporate Finance from the University Complutense, Madrid (UCM), an MBA and PDD IESE from the University of Navarra.